NeuBase Therapeutics Price on July 24, 2023
NBSEDelisted Stock | USD 1.62 0.17 9.50% |
If you're considering investing in NeuBase Stock, it is important to understand the factors that can impact its price. As of today, the current price of NeuBase Therapeutics stands at 1.62, as last reported on the 30th of November, with the highest price reaching 1.83 and the lowest price hitting 1.60 during the day. We have found twenty-four technical indicators for NeuBase Therapeutics, which you can use to evaluate the volatility of the firm. Please verify NeuBase Therapeutics' Mean Deviation of 4.27, risk adjusted performance of (0.12), and Standard Deviation of 6.12 to check out if the risk estimate we provide is consistent with the expected return of 0.0%.
NeuBase Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
NeuBase |
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
NBSE |
Based on monthly moving average NeuBase Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NeuBase Therapeutics by adding NeuBase Therapeutics to a well-diversified portfolio.
Related Headline
Angion Biomedica Headline on 1st of June 2023
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split by finance.yahoo.com
NEWTON, Mass., June 01, 2023 Angion Biomedia Corp. , a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angions common stock will begin trading on a split-adjusted basis when the market opens on June 2, 2023 under the new tradi
NeuBase Therapeutics Valuation on July 24, 2023
It is possible to determine the worth of NeuBase Therapeutics on a given historical date. On July 24, 2023 NeuBase was worth 1.79 at the beginning of the trading date compared to the closed value of 1.62. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of NeuBase Therapeutics stock. Still, in general, we apply an absolute valuation method to find NeuBase Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of NeuBase Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against NeuBase Therapeutics' related companies.
Open | High | Low | Close | Volume | |
1.75 | 1.82 | 1.71 | 1.75 | 46,726 | |
07/24/2023 | 1.79 | 1.83 | 1.60 | 1.62 | 82,886 |
1.79 | 1.83 | 1.60 | 1.62 | 0.00 |
Backtest NeuBase Therapeutics | | | NeuBase Therapeutics History | | | NeuBase Therapeutics Valuation | Previous | Next |
NeuBase Therapeutics Trading Date Momentum on July 24, 2023
On November 30 2024 NeuBase Therapeutics was traded for 1.62 at the closing time. The top price for the day was 1.83 and the lowest listed price was 1.60 . There was no trading activity during the period 0.0. Lack of trading volume on November 30, 2024 did not cause price change. The trading delta at closing time against the current closing price is 10.49% . |
NeuBase Therapeutics Fundamentals Correlations and Trends
By evaluating NeuBase Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among NeuBase Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. NeuBase financial account trend analysis is a perfect complement when working with valuation or volatility modules.About NeuBase Therapeutics Stock history
NeuBase Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for NeuBase is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in NeuBase Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing NeuBase Therapeutics stock prices may prove useful in developing a viable investing in NeuBase Therapeutics
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Neu Base operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
NeuBase Therapeutics Stock Technical Analysis
NeuBase Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
Price Boundaries
NeuBase Therapeutics Period Price Range
Low | November 30, 2024
| High |
0.00 | 0.00 |
NeuBase Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
NeuBase Therapeutics November 30, 2024 Market Strength
Market strength indicators help investors to evaluate how NeuBase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading NeuBase Therapeutics shares will generate the highest return on investment. By undertsting and applying NeuBase Therapeutics stock market strength indicators, traders can identify NeuBase Therapeutics entry and exit signals to maximize returns
NeuBase Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for NeuBase Therapeutics' price direction in advance. Along with the technical and fundamental analysis of NeuBase Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of NeuBase to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.12) | |||
Jensen Alpha | (1.04) | |||
Total Risk Alpha | (2.05) | |||
Treynor Ratio | (8.65) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |